GO:0004135 amylo-alpha-1,6-glucosidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004135 amylo-alpha-1,6-glucosidase activity catalyzes hydrolysis of (1->6)-alpha-D-glucosidic branch linkages in glycogen phosphorylase limit dextrin.
• The enzyme is one of two catalytic activities of the glycogen debranching enzyme (GDE), the other being 4-alpha-glucanotransferase.
• Deficiency of amylo-alpha-1,6-glucosidase activity causes glycogen storage disease type III (GSD III, Cori disease).
• The activity can be measured in leukocytes and cultured cells using fluorogenic substrates for diagnosis.
• Active-site mapping with fluorogenic 6-O-alpha-glucosyl-maltooligosaccharides has defined substrate specificity.
• Altered glycogen debranching is linked to metabolic reprogramming in bladder cancer.
Description
amylo-alpha-1,6-glucosidase activity (GO:0004135) is a molecular function that removes the (1->6)-alpha-D-glucosidic branch points left in glycogen after phosphorylase has trimmed the outer chains. This activity is essential for complete glycogen breakdown because glycogen phosphorylase cannot cleave the (1->6) linkages that create the branched core known as limit dextrin. The reaction is catalyzed by the glycogen debranching enzyme (GDE), a single polypeptide that also carries a 4-alpha-glucanotransferase activity. The two activities cooperate: the transferase moves a short maltosyl or maltotriosyl segment to a nearby non-reducing end, and the glucosidase then hydrolyzes the remaining single glucose residue at the branch point. Because of this dual function, loss of amylo-alpha-1,6-glucosidase activity leads to accumulation of limit dextrin and is the biochemical hallmark of glycogen storage disease type III. Researchers study this activity to understand glycogen turnover, to diagnose GSD III, and to explore metabolic dependencies in cancer and other diseases.
amylo-alpha-1,6-glucosidase activity At A Glance
| GO ID | GO:0004135 |
|---|---|
| GO term | amylo-alpha-1,6-glucosidase activity |
| Ontology | molecular_function |
| Synonym | amylo-1,6-glucosidase activity; amylopectin 1,6-glucosidase activity; dextrin-1,6-glucosidase activity; dextrin 6-alpha-D-glucosidase activity; glycogen phosphorylase-limit dextrin alpha-1,6-glucohydrolase activity |
| Major function | Hydrolysis of (1->6)-alpha-D-glucosidic branch linkages in glycogen phosphorylase limit dextrin |
| Substrate | Glycogen phosphorylase limit dextrin |
| Product | Free glucose and debranched glycogen chains |
| Associated enzyme | Glycogen debranching enzyme (GDE), which also has 4-alpha-glucanotransferase activity |
| Disease link | Deficiency causes glycogen storage disease type III (Cori disease) |
What Is GO:0004135?
In my own words, GO:0004135 describes the catalytic activity that hydrolyzes the (1->6)-alpha-D-glucosidic branch linkages present in glycogen phosphorylase limit dextrin. Limit dextrin is the highly branched core that remains after exhaustive treatment of glycogen with glycogen phosphorylase, because that enzyme cannot hydrolyze (1->6) linkages. The activity therefore releases free glucose from branch points and allows complete degradation of glycogen.
Why Is amylo-alpha-1,6-glucosidase activity Important in Cell Biology?
amylo-alpha-1,6-glucosidase activity is essential for complete glycogen mobilization. Without it, glycogen phosphorylase stalls at branch points, limit dextrin accumulates, and cells cannot access the full energy store of glycogen. This is clinically important because inherited deficiency of this activity causes GSD III, a disease with liver and muscle involvement. The activity is also relevant to cancer metabolism, where glycogen debranching supports growth under hypoxia and contributes to metabolic reprogramming in bladder cancer. Measuring the activity is therefore important for diagnosis, for understanding glycogen turnover, and for evaluating metabolic targets.
• Completes glycogen degradation by removing branch points that phosphorylase cannot cleave.
• Deficiency causes glycogen storage disease type III (Cori disease).
• Enables full energy recovery from glycogen in liver and muscle.
• Provides a diagnostic marker measurable in leukocytes and cultured cells.
• Active-site mapping informs substrate specificity and inhibitor design.
• Isozyme-specific activity ratios help distinguish GDE isozymes.
• Links glycogen metabolism to cancer metabolic reprogramming.
• Supports prenatal and carrier testing in families with GSD III.
• Contributes to understanding of limit dextrin structure and turnover.
• Target for research on metabolic disorders and glycogen storage diseases.
Molecular Mechanism of amylo-alpha-1,6-glucosidase activity
Substrate recognition and limit dextrin formation
In simple terms: The enzyme works on the leftover branched core after glycogen phosphorylase has trimmed glycogen.
Glycogen phosphorylase degrades glycogen until it reaches (1->6) branch points, which it cannot cleave, leaving limit dextrin. amylo-alpha-1,6-glucosidase activity specifically recognizes this limit dextrin and hydrolyzes the (1->6)-alpha-D-glucosidic branch linkages. The enzyme is part of the glycogen debranching enzyme, which also has 4-alpha-glucanotransferase activity that transfers short oligosaccharides to nearby chains.
Catalytic mechanism and active site
In simple terms: The enzyme uses a precise active site to cut the branch point and release free glucose.
Active site mapping using fluorogenic 6-O-alpha-glucosyl-maltooligosaccharides has identified key residues and subsites that determine substrate specificity. The hydrolysis reaction releases free glucose from the branch point, allowing the debranched chain to be further degraded by phosphorylase. The enzyme acts only after the transferase activity has moved the branch to a position where a single glucose remains at the (1->6) linkage.
Isozymes and tissue-specific activity
In simple terms: Different forms of the enzyme exist in different tissues, and their activity ratios can be measured.
Porcine glycogen debranching enzyme isozymes can be discriminated by the ratios of their 4-alpha-glucanotransferase and amylo-alpha-1,6-glucosidase activities. This suggests tissue-specific regulation and possibly different roles in liver versus muscle. Developmental studies in fetal rat liver show that amylo-1,6-glucosidase activity develops and is controlled during gestation.
Regulation and metabolic context
In simple terms: The activity is regulated during development and in response to metabolic needs.
In fetal rat liver, amylo-1,6-glucosidase activity develops and is under developmental control. The activity is also relevant in cancer metabolism, where glycogen debranching supports growth under hypoxia and contributes to metabolic reprogramming in bladder cancer. Targeting glycogen metabolism, including debranching, is being explored as a therapeutic strategy in bladder cancer.
Key Genes Involved in GO:0004135 amylo-alpha-1,6-glucosidase activity
The following genes and proteins are directly or indirectly involved in amylo-alpha-1,6-glucosidase activity and glycogen debranching.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGL | Encodes glycogen debranching enzyme with amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase activities | Mutations cause GSD III; target for diagnosis and gene editing |
| PYGL | Liver glycogen phosphorylase; produces limit dextrin substrate | Defines substrate availability for debranching |
| PYGM | Muscle glycogen phosphorylase; produces limit dextrin in muscle | Muscle-specific glycogen breakdown |
| G6PC | Glucose-6-phosphatase; releases glucose from G6P after debranching | Links debranching to blood glucose homeostasis |
| SLC37A4 | Glucose-6-phosphate transporter | Related glycogen storage disease |
| PPP1R3A | Protein phosphatase 1 regulatory subunit; regulates glycogen metabolism | Regulates glycogen synthase and phosphorylase |
| PPP1R3B | Liver-specific PP1 regulatory subunit | Regulates hepatic glycogen metabolism |
| GSK3A | Glycogen synthase kinase 3 alpha; inhibits glycogen synthase | Upstream regulator of glycogen storage |
| GSK3B | Glycogen synthase kinase 3 beta; inhibits glycogen synthase | Upstream regulator of glycogen storage |
| PRKAA1 | AMPK catalytic subunit alpha 1; promotes energy catabolism | Regulates glycogen metabolism |
| PRKAA2 | AMPK catalytic subunit alpha 2 | Regulates glycogen metabolism |
| HIF1A | Hypoxia-inducible factor 1 alpha; drives metabolic reprogramming | Links glycogen metabolism to cancer |
| EPAS1 | Hypoxia-inducible factor 2 alpha | Hypoxic regulation of metabolism |
| INSR | Insulin receptor; regulates glycogen synthesis and breakdown | Hormonal control of glycogen metabolism |
| AKT1 | Serine/threonine kinase; promotes glycogen synthesis | Insulin signaling |
| AKT2 | Serine/threonine kinase; promotes glycogen synthesis | Insulin signaling |
| PPARGC1A | PGC-1alpha; regulates mitochondrial and metabolic genes | Metabolic regulation |
| FOXO1 | Forkhead box O1; regulates gluconeogenesis and glycogen metabolism | Transcriptional regulation |
How Is amylo-alpha-1,6-glucosidase activity Regulated?
amylo-alpha-1,6-glucosidase activity is regulated at multiple levels. During development, the activity increases in fetal rat liver under developmental control. Hormonal signals such as insulin and glucagon regulate glycogen metabolism upstream, indirectly affecting substrate availability for debranching. In cancer, hypoxia and HIF1A drive metabolic reprogramming that can increase glycogen turnover and debranching activity. Isozyme-specific differences in activity ratios suggest tissue-specific regulation.
amylo-alpha-1,6-glucosidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGL | Glycogen storage disease type III (Cori disease) | Knockout of AGL in HepG2 or primary hepatocytes; patient-derived iPSCs |
| AGL | Muscle involvement in GSD III | Knockout of AGL in C2C12 myotubes |
| HIF1A | Bladder cancer metabolic reprogramming | Knockout or overexpression in bladder cancer cell lines under hypoxia |
| PYGL | Glycogen storage disease type VI | Knockout in hepatocytes |
| PYGM | McArdle disease | Knockout in skeletal muscle cells |
Glycogen storage disease type III (Cori disease)
Deficiency of amylo-alpha-1,6-glucosidase activity causes glycogen storage disease type III (GSD III), also known as Cori disease. Patients accumulate limit dextrin in liver and muscle, leading to hepatomegaly, hypoglycemia, and myopathy. Diagnosis can be confirmed by measuring amylo-1,6-glucosidase activity in leukocytes using fluorimetric assays. Prenatal studies have been performed in cultured cells from affected families.
Bladder cancer and metabolic reprogramming
Glycogen metabolism, including debranching, is altered in bladder cancer. Targeting glycogen metabolism has been proposed as a therapeutic strategy in bladder cancer. The metabolic phenotype of bladder cancer includes changes in glycogen turnover that may depend on debranching activity. These findings link amylo-alpha-1,6-glucosidase activity to cancer biology.
Developmental and metabolic disorders
Developmental control of amylo-1,6-glucosidase activity in fetal rat liver suggests that disruption of this regulation could affect perinatal glucose homeostasis. While direct human developmental disorders are not well characterized, the activity is part of the broader glycogen metabolism network that is critical for energy balance.
From amylo-alpha-1,6-glucosidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AGL cause limit dextrin accumulation? | AGL knockout in HepG2 cells |
| Can a point mutation in the active site abolish glucosidase activity? | Point mutation knock-in of catalytic residues in AGL |
| Does restoring AGL activity rescue GSD III phenotype? | Knock-in of wild-type AGL in patient iPSC-derived hepatocytes |
| Where is AGL localized in cells? | Tagged knock-in of AGL with GFP in HeLa or HepG2 cells |
| Does overexpression of AGL increase glycogen breakdown? | Overexpression of AGL in muscle or liver cell lines |
| Which genes interact with AGL in glycogen metabolism? | CRISPR library screening in glycogen-accumulating cells |
How to Study the amylo-alpha-1,6-glucosidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorogenic substrate assay | amylo-alpha-1,6-glucosidase activity | Diagnosis of GSD III in leukocytes |
| Active site mapping | Substrate specificity and catalytic residues | Enzyme mechanism studies |
| Isozyme activity ratio | Ratio of transferase to glucosidase activity | Discrimination of GDE isozymes |
| CRISPR knockout | Loss-of-function effects | Causal gene testing |
| CRISPR point mutation | Specific residue function | Active site validation |
| CRISPR knock-in | Restoration or tagging | Disease modeling and localization |
| Overexpression | Gain-of-function effects | Metabolic pathway analysis |
| CRISPR library screening | Genome-wide modifiers | Identification of novel regulators |
Enzymatic activity assays
amylo-alpha-1,6-glucosidase activity can be measured using fluorogenic substrates such as 6-O-alpha-glucosyl-maltooligosaccharides. In leukocytes, a fluorimetric assay has been evaluated for confirming GSD III diagnosis. These assays are essential for clinical and research applications.
Genetic and genomic methods
CRISPR knockout, point mutation, and knock-in models allow causal testing of AGL and related genes. CRISPR library screening can identify modifiers of glycogen debranching. Bioinformatics analysis of genomic data can reveal mutations in AGL associated with GSD III.
Metabolic and biochemical profiling
Glycogen and limit dextrin levels can be measured by biochemical assays. Isozyme-specific activity ratios of 4-alpha-glucanotransferase to amylo-alpha-1,6-glucosidase can discriminate GDE isozymes. Developmental studies in fetal rat liver used activity measurements to track regulation.
Cancer metabolism models
Bladder cancer cell lines under hypoxia can be used to study glycogen debranching in metabolic reprogramming. Targeting glycogen metabolism with inhibitors or genetic knockdown can reveal dependencies.
How CRISPR Can Be Used to Study GO:0004135 amylo-alpha-1,6-glucosidase activity
Knockout
CRISPR knockout of AGL or other glycogen metabolism genes can model GSD III and reveal the consequences of loss of amylo-alpha-1,6-glucosidase activity. Knockout cell lines accumulate limit dextrin and can be used to test rescue strategies.
Point Mutation
Point mutations in the active site of AGL can be introduced to test catalytic residues identified by active site mapping. These models help distinguish between glucosidase and transferase activities.
Knock-in
Knock-in of wild-type or tagged AGL allows restoration of activity in patient-derived cells or localization studies. Tagged knock-in with fluorescent proteins enables imaging of the enzyme in live cells.
Overexpression
Overexpression of AGL or other debranching components can increase glycogen breakdown and is useful for studying metabolic flux. Overexpression models can also be used to test inhibitors or activators.
How EDITGENE Supports amylo-alpha-1,6-glucosidase activity Research
Researchers studying amylo-alpha-1,6-glucosidase activity-related genes often need to determine whether a candidate gene is causally involved in glycogen debranching, metabolic disease, or cancer. EDITGENE provides CRISPR-based cell model services to enable such studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for amylo-alpha-1,6-glucosidase activity research.
Frequently Asked Questions About amylo-alpha-1,6-glucosidase activity
What is amylo-alpha-1,6-glucosidase activity?
It is a molecular function (GO:0004135) that hydrolyzes (1->6)-alpha-D-glucosidic branch linkages in glycogen phosphorylase limit dextrin.
What genes are involved in amylo-alpha-1,6-glucosidase activity?
The primary gene is AGL, which encodes the glycogen debranching enzyme. Other genes in glycogen metabolism include PYGL, PYGM, and G6PC.
What disease is caused by deficiency of amylo-alpha-1,6-glucosidase activity?
Deficiency causes glycogen storage disease type III (Cori disease).
How is amylo-alpha-1,6-glucosidase activity measured?
It can be measured using fluorogenic substrates in leukocytes or cultured cells.
What is the role of amylo-alpha-1,6-glucosidase in glycogen breakdown?
It removes branch points that glycogen phosphorylase cannot cleave, allowing complete glycogen degradation.
Is amylo-alpha-1,6-glucosidase activity linked to cancer?
Yes, glycogen debranching is linked to metabolic reprogramming in bladder cancer.
What are the synonyms for amylo-alpha-1,6-glucosidase activity?
Synonyms include amylo-1,6-glucosidase activity, amylopectin 1,6-glucosidase activity, and dextrin-1,6-glucosidase activity.
How does the active site of amylo-alpha-1,6-glucosidase work?
Active site mapping with fluorogenic substrates has identified key residues for substrate specificity.
Can amylo-alpha-1,6-glucosidase activity be studied with CRISPR?
Yes, CRISPR knockout, point mutation, and knock-in models are used to study AGL function.
What is the difference between amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase?
They are two activities of the same glycogen debranching enzyme; the transferase moves branches and the glucosidase hydrolyzes the remaining (1->6) linkage.
Conclusion
amylo-alpha-1,6-glucosidase activity (GO:0004135) is a critical molecular function for complete glycogen degradation. Its deficiency causes GSD III, and it is implicated in cancer metabolism. Researchers can study it using enzymatic assays, CRISPR models, and metabolic profiling. EDITGENE offers comprehensive CRISPR services to accelerate discoveries in this field.
References
- 1. Wang Y et al.. 2022. Substrate Selectivity of a Novel Amylo-α-1,6-glucosidase from Thermococcus gammatolerans STB12.. Foods 11(10) PMID: 35627012
- 2. Yamamoto E et al.. 2007. Active site mapping of amylo-alpha-1,6-glucosidase in porcine liver glycogen debranching enzyme using fluorogenic 6-O-alpha-glucosyl-maltooligosaccharides.. J Biochem 141(5):627-34 PMID: 17317688
- 3. Besley GT et al.. 1983. Amylo-1,6-glucosidase activity in cultured cells: a deficiency in type III glycogenosis with prenatal studies.. Prenat Diagn 3(1):13-9 PMID: 6221240
- 4. Doi S et al.. 2010. Discrimination of porcine glycogen debranching enzyme isozymes by the ratios of their 4-alpha-glucanotransferase and amylo-alpha-1,6-glucosidase activities.. J Biochem 147(6):851-6 PMID: 20164147
- 5. Massari F et al.. 2016. Metabolic phenotype of bladder cancer.. Cancer Treat Rev 45:46-57 PMID: 26975021
- 6. Vaillant R et al.. 1979. [Development and control of liver amylo-1,6-glucosidase activity in the fetal rat].. Can J Biochem 57(10):1245-9 PMID: 120213
- 7. Miadi-Messaoud H et al.. 2011. [Evaluation of a fluorimetric for determining the activity of amylo-1,6-glucosidase in leukocytes for confirming the diagnosis of glycogen storage disease type III].. Ann Biol Clin (Paris) 69(1):41-5 PMID: 21463994
- 8. Ritterson Lew C et al.. 2015. Targeting glycogen metabolism in bladder cancer.. Nat Rev Urol 12(7):383-91 PMID: 26032551
